UCB SA (OTCMKTS:UCBJF – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $231.75, but opened at $250.43. UCB shares last traded at $246.3175, with a volume of 165 shares changing hands.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on UCBJF shares. Jefferies Financial Group raised UCB to a “hold” rating in a research report on Monday, August 3rd. Piper Sandler restated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy”.
Check Out Our Latest Stock Analysis on UCB
UCB Trading Up 6.2%
About UCB
UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.
Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.
Featured Stories
- Five stocks we like better than UCB
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
